Alberta Investment Management Corp Akebia Therapeutics, Inc. Transaction History

Alberta Investment Management Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 14, 2019	SELL	$4.1 - $8.05 $221,809 - $435,505	-54,100 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$5.41 - $8.73 $78,986 - $127,458	14,600 Added 36.96%	54,100 $443,000
Q4 2018 Feb 14, 2019	BUY	$5.39 - $9.15 $212,905 - $361,425	39,500 New	39,500 $218,000
Q3 2018 Nov 16, 2018	SELL	$7.44 - $10.65 $386,880 - $553,800	-52,000 Closed	0 $0
Q2 2018 Aug 15, 2018	SELL	$9.15 - $11.34 $246,135 - $305,046	-26,900 Reduced 34.09%	52,000 $519,000
Q1 2018 May 16, 2018	BUY	$9.53 - $15.68 $339,268 - $558,208	35,600 Added 82.22%	78,900 $752,000
Q4 2017 Feb 15, 2018	BUY	$14.24 - $19.59 $616,592 - $848,247	43,300	43,300 $644,000

121

54.6M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $349M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Alberta Investment Management Corp, based on Form 13F filings with the SEC.

Stay updated on Alberta Investment Management Corp with notifications on news.